News | July 31, 2024
Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
Subscribe To Our Newsletter & Stay Updated
